APA (7th ed.) Citation

Sillesen, H., Amarenco, P., Hennerici, M. G., Callahan, A., Goldstein, L. B., Zivin, J., . . . Welch, K. M. (2008). Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: A secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke, 39(12), . https://doi.org/10.1161/STROKEAHA.108.516450

Chicago Style (17th ed.) Citation

Sillesen, Henrik, Pierre Amarenco, Michael G. Hennerici, Alfred Callahan, Larry B. Goldstein, Justin Zivin, Michael Messig, and K. Michael Welch. "Atorvastatin Reduces the Risk of Cardiovascular Events in Patients with Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial." Stroke 39, no. 12 (2008). https://doi.org/10.1161/STROKEAHA.108.516450.

MLA (9th ed.) Citation

Sillesen, Henrik, et al. "Atorvastatin Reduces the Risk of Cardiovascular Events in Patients with Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial." Stroke, vol. 39, no. 12, 2008, https://doi.org/10.1161/STROKEAHA.108.516450.